Threshold Pharma (THLD) Hits Target Enrollment for TH-302 Phase 3
Tweet Send to a Friend
Threshold Pharmaceuticals, Inc. (Nasdaq: THLD) announced that the target enrollment of 620 patients with advanced soft tissue sarcoma has been ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE